Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Lucas Opazo-Ríos,Sebastian Mas,Gema Marín-Royo,Sergio Mezzano,Carmen Gomez-Guerrero,Juan Antonio Moreno,Jesús Egido +6 more
Reads0
Chats0
TLDR
This review examines the recent preclinical and clinical research about the potentially harmful effects of lipid effects in the kidney, metabolic markers associated with these mechanisms, major signaling pathways affected, the causes of excessive lipid accumulation, and the types of lipids involved, as well as offers a comprehensive update of therapeutic strategies targeting lipotoxicity.Abstract:
Lipotoxicity is characterized by the ectopic accumulation of lipids in organs different from adipose tissue. Lipotoxicity is mainly associated with dysfunctional signaling and insulin resistance response in non-adipose tissue such as myocardium, pancreas, skeletal muscle, liver, and kidney. Serum lipid abnormalities and renal ectopic lipid accumulation have been associated with the development of kidney diseases, in particular diabetic nephropathy. Chronic hyperinsulinemia, often seen in type 2 diabetes, plays a crucial role in blood and liver lipid metabolism abnormalities, thus resulting in increased non-esterified fatty acids (NEFA). Excessive lipid accumulation alters cellular homeostasis and activates lipogenic and glycogenic cell-signaling pathways. Recent evidences indicate that both quantity and quality of lipids are involved in renal damage associated to lipotoxicity by activating inflammation, oxidative stress, mitochondrial dysfunction, and cell-death. The pathological effects of lipotoxicity have been observed in renal cells, thus promoting podocyte injury, tubular damage, mesangial proliferation, endothelial activation, and formation of macrophage-derived foam cells. Therefore, this review examines the recent preclinical and clinical research about the potentially harmful effects of lipids in the kidney, metabolic markers associated with these mechanisms, major signaling pathways affected, the causes of excessive lipid accumulation, and the types of lipids involved, as well as offers a comprehensive update of therapeutic strategies targeting lipotoxicity.read more
Citations
More filters
Journal Article
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes
Carolina E. Hagberg,Annika Mehlem,Annelie Falkevall,Lars Muhl,Barbara C Fam,Henrik Ortsäter,Pierre Scotney,Daniel Nyqvist,Erik Samén,Li Lu,Sharon Stone-Elander,Joseph Proietto,Sofianos Andrikopoulos,Åke Sjöholm,Andrew D. Nash,Ulf Eriksson +15 more
TL;DR: In this article, the authors proposed VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipidtransport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.
Journal ArticleDOI
Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases.
TL;DR: The current roles of adiponectin in metabolic disorders and autoimmune diseases is summarized and knowledge on the specific functions of isoforms would help develop potential anti-inflammatory therapeutics to target specific adiponECTin isoforms against metabolic disordersand autoimmune diseases.
Journal ArticleDOI
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
Amalia Gastaldelli,Enrico Repetto,Cristian Guja,Elise Hardy,Jenny Han,Serge Jabbour,Ele Ferrannini +6 more
TL;DR: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION‐8, a 104‐week study in 695 patients with type 2 diabetes uncontrolled by metformin monotherapy.
Journal ArticleDOI
Glucose and glycogen in the diabetic kidney: Heroes or villains?
TL;DR: This manuscript places into context an area of research highly relevant to renal glucose metabolism, that of glycogen accumulation and metabolism in the diabetic kidney, and investigates whether the glycogen that abnormally accumulates is pathological (the villain), is somehow protective (the hero) or is inconsequential (the bystander).
Journal ArticleDOI
Signaling pathways of chronic kidney diseases, implications for therapeutics
TL;DR: In this paper , the potential therapies targeted to these signaling pathways are also introduced and the key signaling pathways of lipotoxicity, oxidative stress, inflammation, and myofibroblasts activation in kidneys with chronic injury, and the targeted drugs based on the latest studies.
References
More filters
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease
Michael Gleeson,Nicolette C. Bishop,David J. Stensel,Martin R. Lindley,Sarabjit S. Mastana,Myra A. Nimmo +5 more
TL;DR: The known mechanisms by which exercise — both acute and chronic — exerts its anti-inflammatory effects are focused on, and the implications of these effects for the prevention and treatment of disease are discussed.
Journal ArticleDOI
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities.
TL;DR: Cytokines and nutrients trigger beta-cell death by fundamentally different mechanisms, namely an NF-kappaB-dependent mechanism that culminates in caspase-3 activation for cytokines and anNF-kappB-independent mechanism for nutrients.
Journal ArticleDOI
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
TL;DR: Widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease, and characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms are needed.
Journal ArticleDOI
Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity
Alan Dresner,Didier Laurent,Melissa Marcucci,Margaret E. Griffin,Sylvie Dufour,Gary W. Cline,Lori A. Slezak,Dana K. Andersen,Ripudaman S. Hundal,Douglas L. Rothman,Kitt Falk Petersen,Gerald I. Shulman +11 more
TL;DR: Data suggest that increased concentrations of plasma FFA induce insulin resistance in humans through inhibition of glucose transport activity; this may be a consequence of decreased IRS-1-associated PI 3-kinase activity.